Amgen Inc Drug Patent Portfolio

Amgen Inc owns 3 orange book drugs protected by 27 US patents Given below is the list of Amgen Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11426404 Dosing of KRAS inhibitor for treatment of cancers 15 Sep, 2040
Active
US11236091 Solid state forms 20 May, 2040
Active
US11827635 Solid state forms 20 May, 2040
Active
US10519146 KRAS G12C inhibitors and methods of using the same 21 May, 2038
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 Nov, 2034
Active
US9872854 Methods for the treatment of psoriatic arthritis using apremilast 29 Nov, 2034
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 May, 2034
Active
US9872854 Methods for the treatment of psoriatic arthritis using apremilast 29 May, 2034
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Aug, 2028
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Feb, 2028
Active
US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Jun, 2027
Active
US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Dec, 2026
Active
US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
Active
US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
Active
US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
Active
US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
Active
US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
Active
US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
Active
US7893101 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 09 Dec, 2023 Expired
US6962940 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof 19 Mar, 2023 Expired
US7208516 Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023 Expired
US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione 19 Mar, 2023 Expired
US8455536 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023 Expired
US8802717 Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023 Expired
US9018243 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 19 Mar, 2023 Expired
US9724330 Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023 Expired
US6020358 Substituted phenethylsulfones and method of reducing TNFα levels 30 Oct, 2018 Expired


Given below is the list of recent legal activities going on the following drug patents of Amgen Inc.

Activity Date Patent Number
Patent litigations
Email Notification 29 Nov, 2023 US11827635
Recordation of Patent eGrant 28 Nov, 2023 US11827635
Patent eGrant Notification 28 Nov, 2023 US11827635
Mail Patent eGrant Notification 28 Nov, 2023 US11827635
Recordation of Patent Grant Mailed 28 Nov, 2023 US11827635
Patent Issue Date Used in PTA Calculation 28 Nov, 2023 US11827635
Email Notification 09 Nov, 2023 US11827635
Issue Notification Mailed 08 Nov, 2023 US11827635
Application Is Considered Ready for Issue 25 Oct, 2023 US11827635
Dispatch to FDC 25 Oct, 2023 US11827635
Issue Fee Payment Received 23 Oct, 2023 US11827635
Issue Fee Payment Verified 23 Oct, 2023 US11827635
Electronic Review 09 Aug, 2023 US11827635
Email Notification 09 Aug, 2023 US11827635
Mail Notice of Allowance 09 Aug, 2023 US11827635


Amgen Inc Drug Patents' Oppositions Filed in EPO

Amgen Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 26, 2010, by Ratiopharm Gmbh. This opposition was filed on patent number EP03721414A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP10162667A Mar, 2020 Galenicum Health S.L.U. Revoked
EP10162667A Feb, 2020 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Revoked
EP10162667A Feb, 2020 Zentiva k.s. Revoked
EP10162667A Feb, 2020 Hexal AG Revoked
EP10162667A Feb, 2020 Wuesthoff & Wuesthoff Patentanwälte PartG mbB Revoked
EP15177140A Oct, 2019 KRKA, d.d., Novo mesto Granted and Under Opposition
EP15177140A Oct, 2019 Galenicum Health S.L.U. Granted and Under Opposition
EP15177140A Oct, 2019 Zentiva k.s. Granted and Under Opposition
EP15177140A Oct, 2019 Cipla Ltd Granted and Under Opposition
EP15177140A Oct, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP15177140A Oct, 2019 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP15177140A Oct, 2019 Dr. Reddy's Laboratories Limited Granted and Under Opposition
EP15177140A Oct, 2019 Hexal AG Granted and Under Opposition
EP15177140A Oct, 2019 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Granted and Under Opposition
EP15177140A Oct, 2019 Química Sintética, S.A. Granted and Under Opposition
EP15177140A Oct, 2019 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP15177140A Oct, 2019 Generics (UK) Ltd Granted and Under Opposition
EP15177140A Oct, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP15177140A Oct, 2019 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Granted and Under Opposition
EP15177140A Oct, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP10162653A Feb, 2018 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Revoked
EP09003138A Jul, 2017 Accord Healthcare Revoked
EP03721414A May, 2010 Ratiopharm GmbH Revoked


Amgen Inc's Family Patents

Amgen Inc drugs have patent protection in a total of 52 countries. It's US patent count contributes only to 17.7% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Amgen Inc Drug List

Given below is the complete list of Amgen Inc's drugs and the patents protecting them.


1. Corlanor

Corlanor is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7867996
(Pediatric)
γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Jun, 2027
(2 years from now)
Active
US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Dec, 2026
(2 years from now)
Active
US7361649
(Pediatric)
β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
(1 year, 10 months from now)
Active
US7361650
(Pediatric)
γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
(1 year, 10 months from now)
Active
US7879842
(Pediatric)
Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
(1 year, 10 months from now)
Active
US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
(1 year, 4 months from now)
Active
US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
(1 year, 4 months from now)
Active
US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
(1 year, 4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Corlanor's drug page


2. Lumakras

Lumakras is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11426404 Dosing of KRAS inhibitor for treatment of cancers 15 Sep, 2040
(15 years from now)
Active
US11236091 Solid state forms 20 May, 2040
(15 years from now)
Active
US11827635 Solid state forms 20 May, 2040
(15 years from now)
Active
US10519146 KRAS G12C inhibitors and methods of using the same 21 May, 2038
(13 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumakras's drug page


3. Otezla

Otezla is protected by 15 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10092541
(Pediatric)
Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 Nov, 2034
(10 years from now)
Active
US9872854
(Pediatric)
Methods for the treatment of psoriatic arthritis using apremilast 29 Nov, 2034
(10 years from now)
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 May, 2034
(9 years from now)
Active
US9872854 Methods for the treatment of psoriatic arthritis using apremilast 29 May, 2034
(9 years from now)
Active
US7427638
(Pediatric)
(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Aug, 2028
(3 years from now)
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Feb, 2028
(3 years from now)
Active
US7893101 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 09 Dec, 2023
(10 months ago)
Expired
US6962940 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof 19 Mar, 2023
(1 year, 6 months ago)
Expired
US7208516 Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023
(1 year, 6 months ago)
Expired
US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione 19 Mar, 2023
(1 year, 6 months ago)
Expired
US8455536 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023
(1 year, 6 months ago)
Expired
US8802717 Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023
(1 year, 6 months ago)
Expired
US9018243 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 19 Mar, 2023
(1 year, 6 months ago)
Expired
US9724330 Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023
(1 year, 6 months ago)
Expired
US6020358 Substituted phenethylsulfones and method of reducing TNFα levels 30 Oct, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Otezla's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List